Table 3 Relative risk of patient with scleritis having a specified underlying systemic condition
From: Health system wide “big data” analysis of rheumatologic conditions and scleritis
Condition | RR | 95% CI | p | E-value for RR | E-value for 95% lower CI |
|---|---|---|---|---|---|
GPA | 115 | 86–153 | 0 | 229 | 172 |
PAN | 66 | 36.8–118 | 3.00E-155 | 131 | 73 |
Behcet | 48 | 23.2–101 | 1.00E-72 | 96 | 46 |
Sjogrens | 25.1 | 20.9–30 | 0 | 50 | 41 |
RA | 20.2 | 17.4–23.5 | 0 | 40 | 34 |
Lupus | 15 | 12–18.7 | 2.00E-229 | 29 | 23 |
MCTD | 14.6 | 10–21.2 | 3.00E-76 | 28 | 19 |
JIA/JRA | 14.6 | 7.6–28 | 1.00E-26 | 29 | 15 |
PMR / GCA | 14.3 | 9.9–20.5 | 8.60E-80 | 28 | 19 |
HLA-B27 | 12.6 | 107–14.8 | 0 | 25 | 21 |
Sarcoid | 11.4 | 8.3–15.5 | 1.00E-84 | 22 | 16 |
Scleroderma | 8.8 | 5.5–14.2 | 2.00E-27 | 17 | 10 |
MS | 6.6 | 4.6–9.4 | 8.00E-33 | 13 | 9 |
Gout | 4.4 | 3.6–5.3 | 6.00E-56 | 8 | 7 |